Control of red blood cell mass in spaceflight.
The effect of spaceflight on red blood cell mass (RBCM), plasma volume (PV), erythron iron turnover, serum erythropoietin, and red blood cell (RBC) production and survival and indexes were determined for six astronauts on two shuttle missions, 9 and 14 days in duration, respectively. PV decreased within the first day. RBCM decreased because of destruction of RBCs either newly released or scheduled to be released from the bone marrow. Older RBCs survived normally. On return to Earth, plasma volume increased, hemoglobin concentration and RBC count declined, and serum erythropoietin increased. We propose that entry into microgravity results in acute plethora as a result of a decrease in vascular space. PV decreases, causing an increase in hemoglobin concentration that effects a decrease in erythropoietin or other growth factors or cytokines. The RBCM decreases by destruction of recently formed RBCs to a level appropriate for the microgravity environment. Return to Earth results sequentially in acute hypovolemia as vascular space dependent on gravity is refilled, an increase in plasma volume, a decrease in hemoglobin concentration (anemia), and an increase in serum erythropoietin.
Alfrey
C P
CP
Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Udden
M M
MM
Leach-Huntoon
C
C
Driscoll
T
T
Pickett
M H
MH
D000222:Adaptation, Physiological / Q000502:physiology; D000328:Adult; D001853:Bone Marrow / Q000502:physiology; D001854:Bone Marrow Cells; D002860:Chromium Radioisotopes; D004905:Erythrocyte Aging / Q000502:physiology; D004909:Erythrocyte Indices; D004912:Erythrocytes / Q000502:physiology*; D004920:Erythropoiesis / Q000502:physiology; D004921:Erythropoietin / Q000378:metabolism; D005260:Female; D006801:Humans; D007501:Iron / Q000097:blood; D008297:Male; D008875:Middle Aged; D010953:Plasma Volume / Q000502:physiology; D011865:Radioisotope Dilution Technique; D012039:Regional Blood Flow / Q000502:physiology; D013026:Space Flight; D014893:Weightlessness / Q000009:adverse effects
D002860:Chromium Radioisotopes; D004921:Erythropoietin; D007501:Iron